Last reviewed · How we verify

NCT05641545

IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients

Terminated Phase 1 Last updated 19 September 2024
What this trial tests

Phase 1 trial testing IVAC in Advanced Renal Cell Carcinoma in 1 participant. Terminated before completion.

Timeline
17 October 2022
Primary endpoint
15 September 2024
15 September 2024

Quick facts

Lead sponsorSLK Kliniken Heilbronn GmbH
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment1
Start date17 October 2022
Primary completion15 September 2024
Estimated completion15 September 2024
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

SLK Kliniken Heilbronn GmbH — full company profile →

Who can join

18 and older, any sex, with Advanced Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a monocenter, single-arm, prospective phase Ib trial, designed to evaluate the safety, clinical toxicity and in vivo immunological effects of a patient-individualized peptide vaccination added to standard of care checkpoint blockade (nivolumab) in adult patients with metastatic/advanced renal cell carcinoma who experienced at least stable disease after four cycles of standard of care immune therapy (ipilimumab/nivolumab).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Harnessing innate immune pathways for therapeutic advancement in cancer.
    Hu A, Sun L, Lin H, Liao Y, et al · · 2024 · cited 150× · PMID 38523155 · DOI 10.1038/s41392-024-01765-9
  2. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
    Meng L, Collier KA, Wang P, Li Z, et al · · 2023 · cited 48× · PMID 38201238 · DOI 10.3390/cells13010034
  3. Neoantigen cancer vaccines: a new star on the horizon.
    Li X, You J, Hong L, Liu W, et al · · 2023 · cited 31× · PMID 38164734 · DOI 10.20892/j.issn.2095-3941.2023.0395
  4. Plasmacytoid dendritic cells at the forefront of anti-cancer immunity: rewiring strategies for tumor microenvironment remodeling.
    Monti M, Ferrari G, Gazzurelli L, Bugatti M, et al · · 2024 · cited 22× · PMID 39020402 · DOI 10.1186/s13046-024-03121-9
  5. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
    Jang A, Lichterman JN, Zhong JY, Shoag JE, et al · · 2023 · cited 8× · PMID 37947202 · DOI 10.1080/21645515.2023.2276629
  6. Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
    Compagno S, Casadio C, Galvani L, Rosellini M, et al · · 2024 · cited 7× · PMID 39407796 · DOI 10.3390/jcm13195738
  7. Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
    Xie N, Shen G, Huang C, Zhu H. · · 2025 · cited 2× · PMID 40757404 · DOI 10.1097/cm9.0000000000003708
  8. Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.
    Ouyang D, Chen R, Xie H, Yang X, et al · · 2025 · cited 1× · PMID 41311391 · DOI 10.1016/j.apsb.2025.09.007

Verify or expand the search:

Other recruiting trials for Advanced Renal Cell Carcinoma

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05641545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing